Objective: To analyze the clinical effect of interventional devascularization in the treatment of liver cirrhosis with portal hypertension. Methods: 80 patients with liver cirrhosis and portal hypertension admitted between January 2020 and January 2023 were selected as research subjects. They were divided into a control group (surgical devascularization) and an experimental group (interventional devascularization) through the computer grouping method, and the effect of the treatment received by both groups were compared. Results: (i) The efficacy of the treatment received in the experimental group was 94.87%, which was significantly higher than that of the control group, which was 76.92% (P < 0.05). (ii) There was no difference in the levels of alanine transaminase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) between the control group and the experimental group before treatment (P > 0.05); after treatment, the levels of ALT, AST, and ALP in the experimental group were statistically significantly lower than those in the control group (P < 0.05). (iii) Compared with the total complication rate of 28.21% in the control group, the total complication rate of the experimental group was lower at 10.25%, and the statistical significance was established (P < 0.05). Conclusion: Interventional devascularization has demonstrated positive outcomes in treating liver cirrhosis and portal hypertension. This is evident in the enhancement of liver function and its high safety profile. Consequently, it merits wider adoption and utilization in clinical practice.